Your browser is no longer supported. Please, upgrade your browser.
Settings
IPHA [NASD]
Innate Pharma S.A.
Index- P/E- EPS (ttm)- Insider Own1.55% Shs Outstand79.01M Perf Week-12.05%
Market Cap559.38M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float51.13M Perf Month109.29%
Income- PEG- EPS next Q- Inst Own0.38% Short Float0.15% Perf Quarter105.22%
Sales70.45M P/S7.94 EPS this Y- Inst Trans- Short Ratio0.03 Perf Half Y52.92%
Book/sh- P/B- EPS next Y- ROA- Target Price7.14 Perf Year68.97%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range3.02 - 11.95 Perf YTD73.11%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-40.75% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low134.44% ATR0.93
Employees244 Current Ratio- Sales Q/Q26.40% Oper. Margin- RSI (14)65.18 Volatility8.00% 19.15%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.10 Prev Close6.70
ShortableYes LT Debt/Eq- EarningsSep 15 BMO Payout- Avg Volume2.33M Price7.08
Recom1.80 SMA2022.33% SMA5064.71% SMA20066.36% Volume234,892 Change5.67%
Sep-03-21Upgrade SVB Leerink Mkt Perform → Outperform $7
Dec-15-20Downgrade SVB Leerink Outperform → Mkt Perform $7 → $5
Nov-24-20Initiated Goldman Neutral $4.75
Sep-23-21 01:00AM  
Sep-20-21 04:58AM  
Sep-17-21 03:10PM  
01:21PM  
10:10AM  
07:45AM  
07:45AM  
07:06AM  
Sep-15-21 01:00AM  
Sep-09-21 10:39PM  
Sep-07-21 01:00AM  
Sep-03-21 12:48PM  
07:01AM  
Sep-02-21 12:05PM  
12:03PM  
02:00AM  
Aug-30-21 01:00AM  
Aug-11-21 01:00AM  
Jul-12-21 01:00AM  
Jul-06-21 07:16AM  
01:00AM  
01:00AM  
Jun-22-21 09:32AM  
07:00AM  
07:00AM  
Jun-16-21 01:00AM  
Jun-14-21 01:00AM  
Jun-10-21 01:00AM  
Jun-09-21 06:00AM  
06:00AM  
May-28-21 04:01PM  
May-25-21 01:00AM  
May-12-21 01:00AM  
May-11-21 01:00AM  
May-04-21 01:00AM  
Apr-28-21 01:00AM  
01:00AM  
Apr-21-21 01:00AM  
01:00AM  
Apr-19-21 01:00AM  
01:00AM  
Mar-18-21 02:00AM  
02:00AM  
Mar-16-21 02:00AM  
02:00AM  
Feb-24-21 01:00AM  
Feb-17-21 01:00AM  
01:00AM  
Feb-09-21 07:30AM  
07:19AM  
01:00AM  
01:00AM  
Feb-03-21 01:00AM  
01:00AM  
Jan-05-21 01:00AM  
01:00AM  
Jan-04-21 01:00AM  
Dec-22-20 12:00PM  
10:00AM  
09:12AM  
12:35AM  
Dec-21-20 07:31PM  
07:13PM  
12:54PM  
12:30PM  
11:30AM  
11:00AM  
Dec-20-20 01:10PM  
01:00PM  
Dec-19-20 02:25PM  
08:25AM  
Dec-18-20 08:00PM  
07:00PM  
01:00PM  
12:15PM  
11:47AM  
11:15AM  
Dec-17-20 07:45PM  
Dec-16-20 02:05PM  
12:00PM  
11:00AM  
Dec-15-20 06:52PM  
11:00AM  
Dec-14-20 01:00PM  
12:25PM  
11:00AM  
Dec-12-20 10:31PM  
Dec-11-20 03:10PM  
12:20PM  
01:00AM  
Dec-10-20 01:15PM  
Dec-09-20 10:45PM  
04:25PM  
04:00PM  
12:00PM  
11:45AM  
11:15AM  
10:00AM  
09:06AM  
Dec-08-20 12:20PM  
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sezary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; and IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway. Its products in preclinical trials include IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH61, NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, an anti-MICA/B antibody drug conjugate; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; Anti-Siglec-9, an antibody program; IPH25, a checkpoint inhibitor; and IPH62, an NKp46-NKCE platform. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.